HomeCompareCIHKY vs ABBV

CIHKY vs ABBV: Dividend Comparison 2026

CIHKY yields 6.15% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIHKY wins by $134.3K in total portfolio value· pulled ahead in Year 2
10 years
CIHKY
CIHKY
● Live price
6.15%
Share price
$31.93
Annual div
$1.96
5Y div CAGR
36.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.6K
Annual income
$97,622.70
Full CIHKY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CIHKY vs ABBV

📍 CIHKY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIHKYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIHKY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIHKY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIHKY
Annual income on $10K today (after 15% tax)
$523.02/yr
After 10yr DRIP, annual income (after tax)
$82,979.30/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CIHKY beats the other by $61,923.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIHKY + ABBV for your $10,000?

CIHKY: 50%ABBV: 50%
100% ABBV50/50100% CIHKY
Portfolio after 10yr
$169.5K
Annual income
$61,197.23/yr
Blended yield
36.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CIHKY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIHKY buys
0
ABBV buys
0
No recent congressional trades found for CIHKY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIHKYABBV
Forward yield6.15%3.06%
Annual dividend / share$1.96$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR36.5%40.6%
Portfolio after 10y$236.6K$102.3K
Annual income after 10y$97,622.70$24,771.77
Total dividends collected$199.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CIHKY vs ABBV ($10,000, DRIP)

YearCIHKY PortfolioCIHKY Income/yrABBV PortfolioABBV Income/yrGap
1$11,540$839.91$11,550$430.00$10.00ABBV
2← crossover$13,584$1,236.47$13,472$627.96+$112.00CIHKY
3$16,392$1,856.79$15,906$926.08+$486.00CIHKY
4$20,398$2,858.29$19,071$1,382.55+$1.3KCIHKY
5$26,363$4,537.39$23,302$2,095.81+$3.1KCIHKY
6$35,689$7,481.15$29,150$3,237.93+$6.5KCIHKY
7$51,108$12,920.04$37,536$5,121.41+$13.6KCIHKY
8$78,288$23,602.62$50,079$8,338.38+$28.2KCIHKY
9$129,891$46,122.97$69,753$14,065.80+$60.1KCIHKY
10$236,606$97,622.70$102,337$24,771.77+$134.3KCIHKY

CIHKY vs ABBV: Complete Analysis 2026

CIHKYStock

China Merchants Bank Co., Ltd., together with its subsidiaries, provides various banking products and services. It operates through Wholesale Finance Business, Retail Finance Business, and Other Business segments. The company offers current, demand, time, call, savings, notice, and renminbi accounts. Its loan products include personal commercial real estate, consumption, housing, and car loans; loans to finance for studying abroad; micro-business loans; mortgage loans for equipment; joint guarantee, special guarantee, and housing mortgage loan; bank acceptance, discount, liquid capital, and fixed asset loans; and loans for vessels. The company also offers credit cards; insurance products; open-ended funds; discount and guarantees for commercial bills, redemption of commercial bills, and guaranteed discount for commercial acceptance bills; and financial consultation, debt financing underwriting, merger and acquisition financing, and equity financing and enterprise listing services. In addition, it provides forfeiting and risk participation, escrow, cross-border RMB clearing, and interbank services; and risk and financial management, cross-border RMB and oversea financing, international factoring and settlement, and trade finance services. Further, the company offers financial leasing and guarantee, investment and wealth management, forex option and gold trading, forex express trading, international, offshore and private banking, custody, pension, and electronic banking services. As of December 31, 2021, it operated 143 branches; 1,770 sub-branches; one branch-level operation center; 2,812 self-service centers; 6,592 self-service machines; one representative office; 14,746 visual counters in Mainland China. The company also operates in Hong Kong, New York, London, Singapore, Luxembourg, Sydney, and Taipei. China Merchants Bank Co., Ltd. was founded in 1987 and is headquartered in Shenzhen, China.

Full CIHKY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CIHKY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIHKY vs SCHDCIHKY vs JEPICIHKY vs OCIHKY vs KOCIHKY vs MAINCIHKY vs JNJCIHKY vs MRKCIHKY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.